ClinicalTrials.gg
RecruitingNCT05796505Updated Nov 12, 2026

Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement

An interventional study of ADVANCE Steering Committee interventions in COVID-19, Respiratory Viral Infection and Infections, Respiratory, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Yale University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.
Updated Nov 12, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
37,122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in COVID-19 by Yale University — 1 open to participants now, 1 under way, none of them phase 3. COVID-19 · Yale University.

Planned enrollment
3rd of 17
37,122 · median 63
Started
2024
with 5 others
No phase
11 of 20
1 open now
Registered
15th of 20
by date

Among the 20 studies in COVID-19 by Yale University, this one is the 3rd largest by planned enrollment of the 17 interventional ones that give a count, is one of 6 that started in 2024, is one of 11 with no phase, and was the 15th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 20 studies in COVID-19 by Yale University is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in COVID-19 by Yale University, or all of them as a file.
02

Study summary

The objective of this study is to identify a set of interventions that are effective in improving preventive healthcare engagement, including vaccination and chronic disease prevention, among incarcerated individuals and correctional staff in the Pennsylvania prison system.

Read the detailed description

Aim 1: Identify promising strategies and implementation approaches for respiratory preventive health engagement, including vaccination, among correctional staff and formerly incarcerated individuals from high-performing correctional systems.

Aim 2: Select community-endorsed prevention strategies for a statewide correctional system.

Aim 3: Test the effectiveness of strategies to improve respiratory preventive health engagement using rapid-cycle, cluster randomized trials and related evaluative activities, as applicable.

03

Conditions studied

  • COVID-19
  • Respiratory Viral Infection
  • Infections, Respiratory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All incarcerated people in the Pennsylvania DOC are included in the study population for these low risk interventions. In this each individual intervention, inclusion criteria will be based on where incarcerated people are housed and therefore what intervention they will be exposed to.

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria will likely include severe physical or mental illness as these individuals are often incarcerated in special units which will not be included in the study (i.e. medical units).
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37,122 participants (estimated)

Study arms

  • No intervention
    Treatment as usual

    Participants receive standard interventions currently in use (treatment as usual).

  • Experimental
    ADVANCE Steering Committee chosen interventions

    Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.

    Behavioral: ADVANCE Steering Committee interventions

Interventions

  • BehavioralADVANCE Steering Committee interventions

    Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.

06

What researchers measure

Primary outcomes

  1. COVID-19 vaccine acceptance rate

    Acceptance rate amongst incarcerated people and correctional staff assessed as the number of participants that receive a COVID-19 vaccine dose or complete the COVID-19 vaccine series by electronic health record (EHR) or self report inclusive of boosters.

    Time frame: up to 12 weeks post intervention

Secondary outcomes

  1. Respiratory infections rate

    Number of participants with respiratory infections by EHR or self report.

    Time frame: up to 12 weeks post intervention

  2. Hospitalization Rate

    Total number of new admissions for COVID-19 infections by EHR or self report.

    Time frame: up to 12 weeks post intervention

  3. Deaths

    Number of deaths from COVID-19 infections by EHR

    Time frame: up to 12 weeks post intervention

  4. Influenza vaccine acceptance rate

    Vaccine acceptance rate assessed by number of vaccines administered/total number fully vaccinated at start of the intervention

    Time frame: up to 12 weeks post intervention

07

Study locations

1 of 1 sites recruiting
  • Pennsylvannia Department of Corrections
    Schwenksville, Pennsylvania 19473, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 29 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2023
First posted
Apr 3, 2023
StartActual
Jul 23, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionCOVID-19 vaccine acceptance rate: how it is measured was reworded
Nov 12, 2026
Secondary outcomes
1 edited, 1 time frame changed, 1 added, 3 removed
What changed in the outcomes
  • EditedVaccine refusalInfluenza vaccine acceptance rateTime frame: up to 12 weeks post intervention
  • AddedRespiratory infections rateTime frame: up to 12 weeks post intervention
  • RemovedCOVID-19 infectionsTime frame: up to 12 weeks post intervention
  • RemovedChange in vaccination for other respiratory outbreaksTime frame: up to 12 weeks
  • RemovedVaccine acceptance rateTime frame: up to 12 weeks post intervention
  • Time frameDeathsup to 12 weeks → up to 12 weeks post intervention
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionCOVID-19 vaccine acceptance rate: how it is measured was reworded
    Secondary outcomes 1 edited, 1 time frame changed, 1 added, 3 removed
    What changed in the outcomes
    • EditedVaccine refusalInfluenza vaccine acceptance rateTime frame: up to 12 weeks post intervention
    • AddedRespiratory infections rateTime frame: up to 12 weeks post intervention
    • RemovedCOVID-19 infectionsTime frame: up to 12 weeks post intervention
    • RemovedChange in vaccination for other respiratory outbreaksTime frame: up to 12 weeks
    • RemovedVaccine acceptance rateTime frame: up to 12 weeks post intervention
    • Time frameDeathsup to 12 weeks → up to 12 weeks post intervention
    + 5 other changes: index terms, verification date, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05796505
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
Jul 23, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Lisa B Puglisi, MD
Contact
Lisa.puglisi@yale.edu
475-306-1023
Lisa B Puglisi, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion